文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

通过空间和单细胞转录组学定义的腔型乳腺癌的分子特征。

Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.

机构信息

Department of Cancer Biology and Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, California, USA.

Department of Surgery and Oncology, Graduate School of Medicine, Kyushu University, Fukuoka, Japan.

出版信息

Clin Transl Med. 2024 Jan;14(1):e1548. doi: 10.1002/ctm2.1548.


DOI:10.1002/ctm2.1548
PMID:38282415
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10823285/
Abstract

BACKGROUND: Intratumour heterogeneity is a hallmark of most solid tumours, including breast cancers. We applied spatial transcriptomics and single-cell RNA-sequencing on patient-derived xenografts (PDXs) to profile spatially resolved cell populations within oestrogen receptor-positive (ER ) breast cancer and to elucidate their importance in oestrogen-dependent tumour growth. METHODS: Two PDXs of 'ER-high' breast cancers with opposite oestrogen-mediated growth responses were investigated: oestrogen-suppressed GS3 (80-100% ER) and oestrogen-dependent SC31 (40-90% ER) models. The observation was validated via single-cell analyses on an 'ER-low' PDX, GS1 (5% ER). The results from our spatial and single-cell analyses were further supported by a public ER breast cancer single-cell dataset and protein-based dual immunohistochemistry (IHC) of SC31 examining important luminal cancer markers (i.e., ER, progesterone receptor and Ki67). The translational implication of our findings was assessed by clinical outcome analyses on publicly available cohorts. RESULTS: Our space-gene-function study revealed four spatially distinct compartments within ER breast cancers. These compartments showed functional diversity (oestrogen-responsive, proliferative, hypoxia-induced and inflammation-related). The 'proliferative' population, rather than the 'oestrogen-responsive' compartment, was crucial for oestrogen-dependent tumour growth, leading to the acquisition of luminal B-like features. The cells expressing typical oestrogen-responsive genes like PGR were not directly linked to oestrogen-dependent proliferation. Dual IHC analyses demonstrated the distinct contribution of the Ki67 proliferative cells toward oestrogen-mediated growth and their response to a CDK4/6 inhibitor. The gene signatures derived from the proliferative, hypoxia-induced and inflammation-related compartments were significantly correlated with worse clinical outcomes, while patients with the oestrogen-responsive signature showed better prognoses, suggesting that this compartment would not be directly associated with oestrogen-dependent tumour progression. CONCLUSIONS: Our study identified the gene signature in our 'proliferative' compartment as an important determinant of luminal cancer subtypes. This 'proliferative' cell population is a causative feature of luminal B breast cancer, contributing toward its aggressive behaviours.

摘要

背景:肿瘤内异质性是大多数实体瘤(包括乳腺癌)的一个标志。我们应用空间转录组学和单细胞 RNA 测序对患者来源的异种移植(PDX)进行分析,以描绘雌激素受体阳性(ER )乳腺癌中空间分辨的细胞群体,并阐明它们在雌激素依赖性肿瘤生长中的重要性。

方法:研究了两种具有相反雌激素介导生长反应的“ER 高”乳腺癌 PDX:雌激素抑制的 GS3(80-100% ER)和雌激素依赖的 SC31(40-90% ER)模型。通过对“ER 低”PDX GS1(5% ER)的单细胞分析进行了验证。我们的空间和单细胞分析结果进一步得到了公共 ER 乳腺癌单细胞数据集和基于蛋白质的 SC31 双重免疫组织化学(IHC)的支持,该分析检查了重要的腔癌标志物(即 ER、孕激素受体和 Ki67)。通过对公开可用队列的临床结果分析评估了我们发现的转化意义。

结果:我们的空间-基因-功能研究揭示了 ER 乳腺癌中四个空间上不同的隔室。这些隔室显示出功能多样性(雌激素反应性、增殖性、缺氧诱导和炎症相关)。对于雌激素依赖性肿瘤生长,“增殖性”群体而非“雌激素反应性”隔室至关重要,导致获得腔 B 样特征。表达典型雌激素反应性基因如 PGR 的细胞与雌激素依赖性增殖没有直接联系。双重 IHC 分析表明,Ki67 增殖细胞对雌激素介导的生长及其对 CDK4/6 抑制剂的反应具有明显的贡献。来自增殖、缺氧诱导和炎症相关隔室的基因特征与更差的临床结果显著相关,而具有雌激素反应性特征的患者具有更好的预后,这表明该隔室与雌激素依赖性肿瘤进展没有直接关系。

结论:我们的研究确定了我们“增殖”隔室中的基因特征是腔癌亚型的重要决定因素。这种“增殖”细胞群是腔 B 乳腺癌的一个重要特征,导致其侵袭性行为。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/5a0f89e65d97/CTM2-14-e1548-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/34a0230ce399/CTM2-14-e1548-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/5d9593331f8a/CTM2-14-e1548-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/e9aacae7cd4c/CTM2-14-e1548-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/e6667e104d2c/CTM2-14-e1548-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/3ce8e968dcaf/CTM2-14-e1548-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/07fc81c74cf9/CTM2-14-e1548-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/f2294e03a8a2/CTM2-14-e1548-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/6f12ce6be957/CTM2-14-e1548-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/5a0f89e65d97/CTM2-14-e1548-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/34a0230ce399/CTM2-14-e1548-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/5d9593331f8a/CTM2-14-e1548-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/e9aacae7cd4c/CTM2-14-e1548-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/e6667e104d2c/CTM2-14-e1548-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/3ce8e968dcaf/CTM2-14-e1548-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/07fc81c74cf9/CTM2-14-e1548-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/f2294e03a8a2/CTM2-14-e1548-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/6f12ce6be957/CTM2-14-e1548-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ce/10823285/5a0f89e65d97/CTM2-14-e1548-g003.jpg

相似文献

[1]
Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.

Clin Transl Med. 2024-1

[2]
Identification and characterization of a proliferative cell population in estrogen receptor-positive metastatic breast cancer through spatial and single-cell transcriptomics.

bioRxiv. 2023-2-3

[3]
High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.

Clin Breast Cancer. 2015-6

[4]
RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.

Breast Cancer Res Treat. 2010-8-10

[5]
Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.

Breast Cancer Res Treat. 2014-4

[6]
Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.

Breast Cancer Res. 2010-7-20

[7]
A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis.

Breast Cancer Res. 2008

[8]
Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.

Breast Cancer Res. 2009

[9]
DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.

PLoS One. 2014-1-2

[10]
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.

EBioMedicine. 2022-9

引用本文的文献

[1]
Spatial Transcriptomics Decodes Breast Cancer Microenvironment Heterogeneity: From Multidimensional Dynamic Profiling to Precision Therapy Blueprint Construction.

Biomolecules. 2025-7-24

[2]
MiR-101-3p and miR-106b-5p roles in EMT pathway: prognostic and therapeutic insights for luminal breast cancer.

J Egypt Natl Canc Inst. 2025-7-21

[3]
Intravoxel incoherent motion-based habitat imaging for the prediction of immunohistochemistry in patients with breast cancer.

Front Oncol. 2025-6-27

[4]
The Splice Variant of the NCOR2 Gene BQ323636.1 Modulates ACSL4 Expression to Enhance Fatty Acid Metabolism and Support of Tumor Growth in Breast Cancer.

Int J Mol Sci. 2025-5-22

[5]
Associations Between DNA Repair Gene Polymorphisms and Breast Cancer Histopathological Subtypes: A Preliminary Study.

J Clin Med. 2025-5-27

[6]
Quantifying and interpreting biologically meaningful spatial signatures within tumor microenvironments.

NPJ Precis Oncol. 2025-3-11

[7]
New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment.

Cancers (Basel). 2025-1-7

[8]
Patient-derived xenograft model in cancer: establishment and applications.

MedComm (2020). 2025-1-19

[9]
Advancements in the Application of scRNA-Seq in Breast Research: A Review.

Int J Mol Sci. 2024-12-22

[10]
Spatial transcriptomics in breast cancer: providing insight into tumor heterogeneity and promoting individualized therapy.

Front Immunol. 2024-12-19

本文引用的文献

[1]
SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition.

Commun Biol. 2023-7-6

[2]
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.

Clin Cancer Res. 2023-8-1

[3]
Spatial transcriptomics herald a new era of transcriptome research.

Clin Transl Med. 2023-5

[4]
Initiative of clinical single-cell biomedicine in clinical and translational medicine.

Clin Transl Med. 2023-1

[5]
Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor.

Nat Commun. 2022-6-6

[6]
RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.

J Natl Cancer Inst. 2022-7-11

[7]
Influence of Estrogen Treatment on and Cells in ER Breast Cancer: Insights from Single-Cell Analysis of Patient-Derived Xenograft Models.

Cancers (Basel). 2021-12-19

[8]
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic.

Endocrinology. 2022-1-1

[9]
TXNIP Links Anticipatory Unfolded Protein Response to Estrogen Reprogramming Glucose Metabolism in Breast Cancer Cells.

Endocrinology. 2022-1-1

[10]
A single-cell and spatially resolved atlas of human breast cancers.

Nat Genet. 2021-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索